Nanoviricides Stock Price, News & Analysis

NanoViricides, Inc. (NYSE American: NNVC) announced the initiation of drug development targeting human Adenovirus 41 Type F, linked to severe pediatric hepatitis cases. This decision follows a rise in worldwide cases, with over 450 reported, including 110 in the USA, where hospitalization exceeds 90%. The company's priority remains advancing NV-CoV-2, its COVID-19 drug candidate, toward clinical trials. NanoViricides plans to screen its antiviral library against hAd41-F using its own BSL2 Virology facility.

NanoViricides, Inc. (NNVC) provided an update on its COVID-19 drug candidate NV-CoV-2, nearing completion of the Investigators Medicinal Product Dossier for clinical trial application. The drug exhibits a novel 'Re-infection Blocker' mechanism and is effective against emerging SARS-CoV-2 variants. The company reports sufficient funding for Phase I/II trials and has developed Oral Gummies to improve patient compliance. Manufacturing systems for clinical trial products are being rapidly established, and the company aims to produce drugs for 1,000-5,000 patients in a single batch.

NanoViricides, Inc. (NNVC) has filed its quarterly report for Q2 FY2022, indicating about $17.5 million in current assets and $0.34 million in current liabilities as of December 31, 2021. The company reports no revenues and approximately $2.84 million used in operations over the six-month period. It is pursuing clinical trials for its COVID-19 drug candidate, NV-CoV-2, which shows promise in pre-clinical studies, being more effective than remdesivir. Additionally, the company is developing formulations for oral gummies and inhalation to improve drug delivery.

NanoViricides, Inc. has filed its quarterly report for Q1 FY 2022, revealing approximately $19.89 million in current assets and $0.87 million in current cash liabilities, with no debt. The Company reported no revenues during the period. NanoViricides is advancing its drug candidate NV-CoV-2 for COVID-19 treatment, having developed various formulations, including oral gummies and inhalation drugs. The firm has sufficient funds for initial human clinical trials and plans to proceed with IND applications for multiple drug candidates.

NanoViricides, Inc. (NYSE American:NNVC) announced the development of oral gummies and inhalation formulations for its COVID-19 drug candidate NV-CoV-2. These new formulations aim to benefit both non-hospitalized patients and severely ill hospitalized patients. The company reports strong safety results from animal studies, noting that NV-CoV-2 is non-immunogenic, non-allergenic, and non-mutagenic. With these advancements, they aim to support healthcare systems during the ongoing COVID-19 pandemic.

NanoViricides, Inc. (NYSE American:NNVC) filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021, reporting approximately $20.8 million in cash and cash equivalents and $9.08 million in Property and Equipment. The company raised $10.4 million from an equity offering and $6.1 million under an At Market Issuance Sales Agreement, bolstering its finances. Progress was made on COVID-19 drug candidates with promising animal studies indicating significant effectiveness. However, the company reported a net loss of $8.82 million for the fiscal year, down from $13.45 million the previous year.

NanoViricides, Inc. (NYSE American: NNVC) announced that its drug candidate NV-CoV-2 showed effectiveness against SARS-CoV-2 in a cell culture pseudovirion assay, indicating broad-spectrum pan-coronavirus activity. This suggests the drug could combat evolving variants of the virus. The study revealed NV-CoV-2 inhibits virus infection similarly to a positive control antibody. The company plans to prepare documents for human clinical trials, believing NV-CoV-2 could significantly impact the ongoing pandemic if proven effective.

NanoViricides, Inc. (NYSE American: NNVC) presented updates on its COVID-19 drug development program at the Benzinga Healthcare Small Cap Conference on September 30, 2021. The company is advancing two drug candidates, NV-CoV-2 and NV-CoV-2-R, which target SARS-CoV-2 and its variants. Both candidates demonstrated superior efficacy compared to Remdesivir in animal studies, extending lifespan significantly. NV-CoV-2-R is particularly notable for blocking the virus's lifecycle through dual mechanisms. The company is preparing for clinical trials and emphasizes the potential for oral administration, particularly for pediatric use.

NanoViricides, Inc. (NNVC) announced significant advancements in its COVID-19 treatment candidate NV-CoV-2-R, which incorporates remdesivir. Data showed that encapsulated remdesivir in NV-CoV-2-R resulted in nearly double the plasma retention compared to standard formulations, enhancing antiviral efficacy. Importantly, NV-CoV-2-R exhibited lower toxicity, with only 3% weight loss in test subjects compared to 9.5% with standard remdesivir. This dual-action drug aims to develop a pan-coronavirus therapy, addressing issues with current vaccines and antibodies against evolving variants.